Pramipexole Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-25-D-0012

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Hauppauge, New York, UNITED STATES

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support has issued an award notice under procurement identifier SPE2D2-25-D-0012 for the supply of Pramipexole Tablets. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, indicating a focus on pharmaceuticals and drugs. The primary objective of this procurement is to ensure a reliable supply of Pramipexole Tablets, a medication commonly used in the treatment of Parkinson’s disease and related neurological conditions. The contract is intended to support the medical and pharmaceutical needs of federal agencies, with the place of performance specified as Hauppauge, New York. This location will serve as the central hub for the manufacturing, distribution, or fulfillment of the contract requirements. DLA Troop Support, a federal office responsible for providing logistical and supply chain support to the U.S. military and other federal entities, is the contracting authority for this award. The agency’s commitment to maintaining a robust and responsive pharmaceutical supply chain is reflected in this procurement, which aims to ensure the availability of essential medications for its stakeholders. Key requirements and expected deliverables for this contract include the consistent and timely provision of Pramipexole Tablets that meet all applicable federal quality and safety standards. Contractors are expected to adhere to stringent manufacturing practices and regulatory compliance as outlined for pharmaceutical products under NAICS 325412. While the specific quantities, packaging, and delivery schedules are not detailed in the notice, contractors should anticipate the need for flexibility and responsiveness to DLA’s operational demands. The notice is currently active and was posted on May 5, 2025. Interested parties seeking further information or clarification regarding the award may contact the primary point of contact, Ryan Guarnere, at [email protected] or by phone at 215-737-2571. A secondary contact, Jason Wray, is also available at [email protected] or 215-737-0614. This award notice does not specify any set-aside requirements or special considerations such as small business preferences. Contractors evaluating this opportunity should ensure their capabilities align with the manufacturing, quality assurance, and distribution requirements typical of federal pharmaceutical contracts. The opportunity details and any associated documentation can be accessed via the official SAM.gov listing at https://sam.gov/opp/515191fcde43455ab76b9bbb2a7131c2/view. In summary, this procurement represents a critical component of DLA Troop Support’s mission to provide essential pharmaceuticals to federal agencies, with a focus on quality, reliability, and regulatory compliance throughout the contract lifecycle.